Transcriptional and post-transcriptional regulation of PTH gene expression by vitamin D, calcium and phosphate.
1,25(OH)(2)D(3) the biologically active metabolite of vitamin D is synthesized in the renal proximal tubules from the hepatic metabolite 25 (OH)D. Lack of 1,25(OH)(2)D(3) is relevant to the pathogenesis of secondary hyperparathyroidism, and 1,25(OH)(2)D(3) itself is used effectively in the management of renal failure patients to prevent secondary hyperparathyroidism. The scientific basis of this therapy is the finding that 1,25(OH)(2)D(3) potently decreases PTH gene transcription both in vitro and in vivo.
Sela-Brown
A
A
Minerva Center for Calcium and Bone Metabolism, Nephrology Services, Hadassah University Hospital, Jerusalem, Israel.
Naveh-Many
T
T
Silver
J
J
D000818:Animals; D002117:Calcitriol / Q000494:pharmacology*; D002118:Calcium / Q000494:pharmacology*; D002135:Calcium-Binding Proteins / Q000502:physiology; D037282:Calreticulin; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D010281:Parathyroid Hormone / Q000235:genetics*; D010710:Phosphates / Q000494:pharmacology*; D018167:Receptors, Calcitriol / Q000502:physiology; D051437:Renal Insufficiency / Q000150:complications; D012261:Ribonucleoproteins / Q000502:physiology; D014158:Transcription, Genetic / Q000187:drug effects*
D002135:Calcium-Binding Proteins; D037282:Calreticulin; D010281:Parathyroid Hormone; D010710:Phosphates; D018167:Receptors, Calcitriol; D012261:Ribonucleoproteins; D002117:Calcitriol; D002118:Calcium